• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Inc REGN 3 Star

Last Price$420.21Day Change (%)-0.14%
Open Price$421.09Day Change ($)-0.60
Day Range414.59–422.9152-Week Range267.56–437.64

As of Fri 01/23/2015 06:33 PM EST | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Regeneron and Sanofi Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia

    Regeneron and Sanofi Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia

  2. Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA

    Regeneron and Sanofi Announce Praluentâ„¢ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA

  3. Research and Markets: Corneal Neovascularization - Pipeline Review, H2 2014

    Research and Markets: Corneal Neovascularization - Pipeline Review, H2 2014

  4. A Biotech With a Growing Moat

    Regeneron's moat is widening thanks to recent clinical successes and a productive pipeline; however, investors should wait for a better price before buying.

  5. T. Rowe Price Thrives Despite a Tumultuous 2013

    The firm remains on solid footing after some unexpected manager and analyst departures.

  6. T. Rowe Price Thrives Despite a Tumultuous 2013

    The firm remains on solid footing after some unexpected manager and analyst departures.

  7. Aberdeen to Buy Artio Global Investors

    As part of Aberdeen's acquisition of Artio, some international fund managers to depart. Also, a management change on a T. Rowe Price health-care fund, Columbia hires Putnam's former asset-allocation head, and ClearBridge and Legg Mason Capital Management funds to merge.

  8. Our 5 Nominees for Domestic-Stock Fund Manager of the Year

    Standing out in a good year for stocks.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.